Skip to main content
Caplight Logo









Isomerase Therapeutics Ltd.

Isomerase Therapeutics Ltd.

Private
CambridgeHealthcare & Life Scienceshttps://isomerase.com/

Last Round

Corporate Funding

Aug 15, 2016

Est. Valuation

$15.2M

Total Funding Raised

$3.49M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Isomerase Therapeutics Ltd. is a biotechnology company that provides drug discovery, synthetic biology, and bioprocess development services for pharmaceutical, agricultural, and industrial applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

synthetic biologydrug discoverynatural product discoverymicrobial engineeringantibody-drug conjugateADCpayload engineeringmutasynthesisCROcontract research organizationbiotech servicesenzyme engineeringprocess developmentbiofoundrydrug development platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Isomerase Therapeutics Ltd. Comparables

Compare Isomerase Therapeutics Ltd. with similar companies based on industry and business-model similarity.

Isomerase Therapeutics Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Generare
84%
Hypha Discovery
81%
Ingenza Ltd
78%

Isomerase Therapeutics Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingAug 15, 2016
GrantJun 3, 2016
StrategicJan 13, 2016
GrantMar 1, 2015
SeedApr 4, 2013

Key People

Founding team and executive leadership

Matthew Gregory

CEO and CSO

Executive Team

Steven Moss

Chief Technology Officer

Executive Team

Isomerase Therapeutics Ltd. Investors

Notable investors and investment history

Isomerase Therapeutics Ltd. investors
InvestorRounds
EPSRCGrant
Innovate UKGrant
Biotechnology and Biological Sciences Research CouncilGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 90% MoM, reaching 5.4K.

  • Sep 16, 2025

    Partnering with Regeneron and Abzena on novel payload exploration.

Isomerase Therapeutics Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Isomerase Therapeutics Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Isomerase Therapeutics Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range33
Year Founded2012
Last FundingAug 15, 2016

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?